Siranomics Closes $105 Million Funding from China Investors; Plans IPO

Sirnaomics, a US-China company developing RNAi therapeutics, closed a $105 million Series D round from China investors. The company is developing a portfolio of novel RNAi therapeutics that address a range of diseases including various cancers, fibrosis diseases, metabolic diseases and viral infections. Earlier this year, it announced positive interim results from a Phase IIa study of STP705 for Cutaneous Squamous Cell Carcinoma in-situ. Siranomics, which plans to conduct an IPO in the near future, is headquartered in Maryland , with China operations in Suzhou and Guangzhou . More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.